Basilea Announces That FDA’s Anti-Infective Drugs Advisory Committee Recommends Approval of Isavuconazole for the Treatment of Invasive Aspergillosis and Mucormycosis
Basel, Switzerland, January 22, 2015 – Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced that the U.S. Food and Drug Administration’s (FDA)…